Compare MLEC & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | GOVX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | Cayman Islands | United States |
| Employees | N/A | 17 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.0M |
| IPO Year | N/A | N/A |
| Metric | MLEC | GOVX |
|---|---|---|
| Price | $6.87 | $1.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $200.00 |
| AVG Volume (30 Days) | 32.2K | ★ 61.1K |
| Earning Date | 04-15-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.42 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.12 |
| 52 Week High | $23.22 | $4.40 |
| Indicator | MLEC | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 36.70 |
| Support Level | $0.60 | $0.55 |
| Resistance Level | $7.98 | $4.40 |
| Average True Range (ATR) | 1.00 | 0.15 |
| MACD | -0.55 | -0.02 |
| Stochastic Oscillator | 16.43 | 12.69 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.